CBX2 as a therapeutic target in colorectal cancer: insights into the altered chromatin accessibility via RUNX1-CBX2-MAP4K1 axis
- 13 March 2025
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 44 (13) , 909-926
Abstract
Chromobox homolog 2 (CBX2), a component of the polycomb repressive complex 1, is overexpressed in various cancers, but its specific role in colorectal cancer (CRC) is not fully understood. This study aimed to characterize the functional and regulatory roles of CBX2 in CRC. Tissue microarray analysis revealed the elevated CBX2 levels in tumor compared to adjacent normal tissues, which is significantly correlated with poor prognosis. Gain and loss of function studies demonstrated that CBX2 significantly promoted CRC progression and chemoresistance in cell lines, patient-derived CRC organoids and xenografts. In the AOM/DSS mouse model, treatment with the innovatively-developed cy5-PBAE/siCBX2 nanoparticle significantly reduced tumor aggressiveness. Mechanistic studies unveiled that the transcription factor RUNX1 is the positive regulator of CBX2. RNA-seq, ATAC-seq and CUT & RUN results indicated CBX2 knockdown induced epigenetic changes, especially alterations in chromatin accessibility. Moreover, we further identified MAP4K1 as a target gene of RUNX1-CBX2, with significant clinical and prognostic relevance in CRC. Collectively, these findings suggest the pivotal role of RUNX1-CBX2-MAP4K1 axis in CRC progression and underscore CBX2 as a promising biomarker and therapeutic target. The regulatory function of CBX2 on chromatin accessibility and the role of the RUNX1-CBX2-MAP4K1-pERK axis in the progression of colorectal cancer.Keywords
Funding Information
- National Natural Science Foundation of China (82202828)
- National Natural Science Foundation of China (82104089)
This publication has 36 references indexed in Scilit:
- A review of non-classical MAPK family member, MAPK4: A pivotal player in cancer development and therapeutic interventionInternational Journal of Biological Macromolecules, 2024
- The interplay of p38 MAPK signaling and mitochondrial metabolism, a dynamic target in cancer and pathological contextsBiochemical Pharmacology, 2024
- Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastasesEuropean Journal of Cancer, 2023
- PRC2.1- and PRC2.2-specific accessory proteins drive recruitment of different forms of canonical PRC1Molecular Cell, 2023
- CBX2-mediated suppression of SIAH2 triggers WNK1 accumulations to promote glycolysis in hepatocellular carcinomaExperimental Cell Research, 2023
- SPIB acts as a tumor suppressor by activating the NFkB and JNK signaling pathways through MAP4K1 in colorectal cancer cellsCellular Signalling, 2021
- Homotypic Targeting Delivery of siRNA with Artificial Cancer CellsAdvanced Healthcare Materials, 2020
- Krüppel Expression Levels Are Maintained through Compensatory Evolution of Shadow EnhancersCell Reports, 2016
- Polymeric Nanoparticles for Nonviral Gene Therapy Extend Brain Tumor Survival in VivoACS Nano, 2015
- Pdcd4 knockdown up-regulates MAP4K1 expression and activation of AP-1 dependent transcription through c-MycBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2012